Pavan Sharma’s Post

Pharma API prices fall in China; here is how Indian companies can benefit💡👨🔬 💊 Recent developments in China's pharmaceutical industry have sparked significant interest in the Indian pharmaceutical sector. Over the past few months, there has been a noteworthy decline in the prices of Active Pharmaceutical Ingredients (APIs) in China. This trend is particularly promising for Indian pharmaceutical companies, which heavily rely on imports from China for APIs, intermediates, and bulk drugs. Market sources have reported substantial drops in the prices of various APIs. For instance, the price of the API for paracetamol has plummeted from ₹900 per kg during the peak of the pandemic to ₹250 per kg currently. Similarly, the prices of other key APIs, such as montelukast sodium and meropenem, have experienced significant declines, presenting cost-saving opportunities for Indian pharmaceutical manufacturers. Experts attribute this downward trend in API prices to several factors, including the dissolution of Chinese cartelization, India's strides towards self-sufficiency in certain intermediates, and overcapacity in anticipation of higher demand. These factors have collectively contributed to a favorable environment for Indian pharmaceutical companies, potentially leading to improved operating profit margins in the coming quarters. The reduction in API prices not only enhances the competitiveness of Indian pharmaceutical firms but also aligns with India's broader objective of achieving self-reliance in the healthcare sector. As domestic companies like Lupin, Sun Pharmaceuticals, Glenmark, and others continue to navigate the evolving landscape, the decline in API prices presents an opportunity to strengthen their supply chains and drive greater efficiency in drug manufacturing processes. Overall, the decline in API prices in China holds promise for the Indian pharmaceutical industry, paving the way for enhanced competitiveness, cost savings, and greater self-sufficiency in the production of essential medicines. #sunpharma #pharmamanufacturing #pharmaindustry #glenmarkpharma #drreddy #lupin #cipla

- Rapid Growth: India's pharmaceutical exports have experienced a remarkable 10% increase to reach USD 27.9 billion in the fiscal year 2023-24. - Robust Performance: India's pharmaceutical industry is the third largest by volume and the 13th largest by value in the world, producing more than 60,000 generic drugs across 60 therapeutic categories. Despite global challenges, the Indian pharmaceutical sector has demonstrated resilience and strength, contributing significantly to the nation's economy. - Diverse Markets: Indian pharmaceutical products are being exported to various destinations worldwide, highlighting the global demand and trust in the quality of Indian medications. - Policy Support: The Indian government has been actively supporting the pharmaceutical industry through policies and initiatives aimed at enhancing competitiveness and facilitating ease of doing business. The positive performance is also a testament to the supportive policies and initiatives by the Indian government, fostering an enabling environment for the pharmaceutical industry to thrive and expand its global footprint. - Enhanced Infrastructure: Investments in infrastructure and technology have bolstered the capabilities of Indian pharmaceutical companies, enabling them to meet international standards and requirements. - Employment Opportunities: The growth of pharmaceutical exports is not only beneficial for the industry but also contributes to job creation and economic development in the country. - Contribution to Healthcare: India's pharmaceutical exports play a crucial role in providing affordable healthcare solutions globally, thus contributing to improving public health outcomes worldwide. - Industry Collaboration: Collaboration between government agencies, industry stakeholders, and research institutions has fostered innovation and productivity within the pharmaceutical sector, driving its growth trajectory. - Global Competitiveness: The sustained growth of India's pharmaceutical exports underscores the country's position as a key player in the global pharmaceutical market, competing effectively with other major players.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

Bangladesh's local pharmaceutical companies have thrived on producing low-cost generic drugs, meeting the country's pharmaceutical needs without relying heavily on imports. However, their export growth has been slow, with only a few countries contributing significantly to their export value. To expand globally, these companies must analyze market data, target specific countries, and tailor their strategies accordingly. Currently, their market share in key importing countries remains low, indicating a need for more focused and data-driven approaches.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

🤔 EXPORT TREND India’s share of pharmaceuticals and drugs in the global market is 5.71%. Formulations & Biologics constituted the major portion of India’s exports with a share of 72.54% followed by drug intermediates and bulk drugs. During FY24 (Until February 2024), the exports of drugs and pharmaceuticals stood at US$ 25.02 billion. In FY23, the exports of drugs and pharmaceuticals stood at US$ 25.4 billion. During 2021-22, the country exported pharma products worth US$ 24.59 billion, while in 2020-21, the exports grew at 18% YoY to US$ 24.44 billion. This robust performance was achieved despite the global supply chain disruptions, lockdowns, and subdued manufacturing. The USA, Belgium, South Africa, the UK, and Brazil were India’s top five export destinations in FY23. India played a key role during the COVID-19 pandemic and demonstrated its ability to be a consistent and reliable pharma supplier to the world even during times of crisis. India has the highest number of United States Food and Drug Administration (USFDA) compliant companies with plants outside of the USA. About eight out of 20 global generic companies are from India and over 55% of the exports from the country are to the highly regulated markets. As the country is the biggest vaccine exporter, about 65-70% of the World Health Organization (WHO) vaccine requirements are sourced from

India's pharma exports rise 10% to USD 27.9 bn in FY24 Experts have said that India's pharmaceutical business may exceed USD 130 billion by 2030, supported by expanding market opportunities and heightened demand in the overseas markets. The business stood at over USD 50 billion for the 2022-23. #IndiasPharmaExports | #IndiaPharmaceuticalBuisness | #Overseasmarket | #MarketOpportunities | #Healthnews Read more:

📌 Indian Drug Firms Look For New Opportunities In Saudi Arabia Pharma Market Indian drug firms are exploring opportunities in the Kingdom of Saudi Arabia (KSA), an $8.9 billion pharmaceutical (pharma) market, as the latter is keen to procure more pharma products from India. https://lnkd.in/g52Jczzg 📌 API Industry Facing Leadership Talent Crunch The active pharmaceutical ingredient (API) industry is facing a high churn in leadership talent amid a sharp increase in investments, according to a report by executive search firm WalkWater Talent Advisors. https://lnkd.in/g7b3a5dd 📌 Several Small Pharma Units Told To Halt Operations Over Quality The Central Drugs Standard Control Organisation (CDSCO) has been conducting risk-based inspections of drug manufacturing units as part of a nationwide crackdown on spurious and substandard drugs. https://lnkd.in/gBTWHB76 📌 Odisha To Focus On Pharma Sector To Make Most Of Drug Exports India meets 45 per cent of the requirement of generic drugs in the USA and 25 per cent in the UK. The revenue was $42 million in 2021-22 and is expected to touch $123 million in 2030.  https://lnkd.in/gVPnqSm3 📌 Healthcare, Pharma Sectors To Do Well In Near Future Despite the markets seen to be overpriced, the bull run is likely to continue for a long time to come since the structural growth of the Indian economy will continue, believes Abhishek Tiwari, executive director and Chief Business Officer of PGIM India Mutual Fund. https://lnkd.in/edCRh_Bf #DigitalSuccess #NewsWrap #LifeSciences